Announcements
- Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Key statistics
On Thursday, Gritstone bio Inc (2JQ:BER) closed at 0.694, 6.93% above its 52-week low of 0.649, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6995 |
---|---|
High | 0.736 |
Low | 0.6875 |
Bid | -- |
Offer | -- |
Previous close | 0.694 |
Average volume | 2.63k |
---|---|
Shares outstanding | 108.57m |
Free float | 104.10m |
P/E (TTM) | -- |
Market cap | 85.49m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼